Ensayo clínico en reclutamiento = ; Ensayos clínico en curso = ; Financiado por un miembro del IRDiRC = ; Miembro de una ERN =

Ensayo(s) clínico(s) nacional(es)

ALEMANIA

Hessen
WIESBADEN

The BOOST Trial: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer - FR

AGO Research GmbH

Para más detalles

ALEMANIA

Hessen
WIESBADEN

The BOOST Trial: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer - DE

AGO Research GmbH

Para más detalles

ALEMANIA

Hessen
WIESBADEN

Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer

AGO Research GmbH

Para más detalles

ALEMANIA

Hessen
WIESBADEN

Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer - a randomized Phase III trial - AT

AGO Research GmbH

Para más detalles

ESTADOS UNIDOS

Washington
ADDRESS: NOT PROVIDED - US

Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial

Institution: Information not provided - US

Para más detalles

ESTADOS UNIDOS

Washington
ADDRESS: NOT PROVIDED - US

A prospective, randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer -GB

Institution: Information not provided - US

Para más detalles

Ensayo(s) clínico(s) multinacional(es)

ALEMANIA

Hessen
WIESBADEN

The BOOST Trial: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer

AGO Research GmbH

Para más detalles